- 专利标题: Cell and gene based methods to improve cardiac function
-
申请号: US14122226申请日: 2012-05-29
-
公开(公告)号: US09868937B2公开(公告)日: 2018-01-16
- 发明人: Michael Regnier , Michael Laflamme , Charles Murry , F. Steven Korte , Scott Lundy , Stephen Denison Hauschka , Jeffrey S. Chamberlain , Guy Odom
- 申请人: Michael Regnier , Michael Laflamme , Charles Murry , F. Steven Korte , Scott Lundy , Stephen Denison Hauschka , Jeffrey S. Chamberlain , Guy Odom
- 申请人地址: US WA Seattle
- 专利权人: University of Washington
- 当前专利权人: University of Washington
- 当前专利权人地址: US WA Seattle
- 代理机构: Stoel Rives LLP
- 代理商 Zhi-Xiang (Alex) Oh
- 国际申请: PCT/US2012/039897 WO 20120529
- 国际公布: WO2012/162705 WO 20121129
- 主分类号: C12N5/077
- IPC分类号: C12N5/077 ; C12N9/02 ; A01K67/027 ; A61K48/00 ; C07K14/47 ; C12N15/85 ; A61K9/00 ; A61K35/34 ; C12N7/00 ; C12N15/86
摘要:
Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
公开/授权文献
- US20160186139A1 CELL AND GENE BASED METHODS TO IMPROVE CARDIAC FUNCTION 公开/授权日:2016-06-30
信息查询